title: Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1.
abstract: It has been defined that strong and multispecific cellular immune responses correlate with a better prognosis during the course of chronic diseases. A cross-enhancing effect on the resulting immune response obtained by the coadministration of recombinant hepatitis B virus (HBV) surface and core Ag was recently observed. With the objective of studying the effect of such Ag on the immune response to coinoculated heterologous Ag and vice versa, several formulations containing the recombinant HBV Ag and a multiepitopic protein (CR3) composed by CTL and Th epitopes from HIV-1 were evaluated by s.c. and mucosal administration. Combinations of two and three Ag were evaluated for cellular and humoral immune responses. The results showed that the best Ag combination for nasal immunization was the mixture comprising the CR3 recombinant HIV protein and both HBV Ag. Similarly, it was also the best formulation for s.c. immunization in aluminium phosphate adjuvant. In conclusion, it is possible to induce a Th1 stimulation of the cellular immune response specific for a HIV-based recombinant protein by formulating this Ag with the recombinant HBV Ag.
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba. enrique.iglesias@cigb.edu.cu
authors.forename: Enrique
authors.initials: E
authors.lastname: Iglesias
authors.forename: Rafael
authors.initials: R
authors.lastname: Thompson
authors.forename: Yamilka
authors.initials: Y
authors.lastname: Carrazana
authors.forename: Yadira
authors.initials: Y
authors.lastname: Lobaina
authors.forename: Daymir
authors.initials: D
authors.lastname: García
authors.forename: Jorge
authors.initials: J
authors.lastname: Sánchez
authors.forename: José
authors.initials: J
authors.lastname: García
authors.forename: Otto
authors.initials: O
authors.lastname: Cruz
authors.forename: Emma
authors.initials: E
authors.lastname: Brown
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martin
authors.forename: Verena L
authors.initials: VL
authors.lastname: Muzio
authors.forename: Julio C
authors.initials: JC
authors.lastname: Aguilar
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D004357:Drug Synergism; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D015497:HIV-1 / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage / Q000276:immunology*; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D050506:Mutant Chimeric Proteins / Q000008:administration & dosage / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology*; D014764:Viral Proteins / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D018984:Epitopes, T-Lymphocyte; D006514:Hepatitis B Surface Antigens; D050506:Mutant Chimeric Proteins; D014764:Viral Proteins